Quality improvement needed for rapid review reports: a literature quality assessment based on Cochrane RR evidence-based methodology

快速综述报告需要改进质量:基于Cochrane RR循证方法的文献质量评估

阅读:2

Abstract

OBJECTIVES: The aim of this study was to assess the reporting quality of rapid reviews (RRs) against the Cochrane Rapid Reviews Methodological Guidance to identify areas for improvement. METHODS: A literature quality assessment was conducted through systematic searches in PubMed, the Cochrane Library, and Web of Science until February 28, 2023. An expert guided the search strategy, and the reporting quality of RRs was evaluated. Descriptive statistics were used to summarize reporting quality, and subgroup analyses were performed to examine differences between groups. Categorical variables were compared using the chi-square (χ(2)) test to identify statistically significant differences in reporting adherence across different subgroups. RESULTS: Among the 112 rapid reviews analyzed, fewer than 50% fully reported four key methodological components: topic refinement with stakeholders, eligibility criteria co-definition, risk of bias assessment tools, and protocol/software reporting. Reports published after 2021 demonstrated slightly higher overall quality compared to those published before 2020, with significant improvements in protocol development (Item 2: χ(2) = 10.434, P < 0.0001), PICOS specification (Item 3: χ(2) = 5.378, P = 0.02), and protocol registration (Item 23: χ(2) = 6.638, P = 0.01). Cochrane Rapid Reviews (CRRs) achieved 100% compliance in several key areas, including setting restrictions with justification (Item 4: χ(2) = 52.923, P < 0.001) and study selection (Item 14: χ(2) = 14.897, P < 0.001). The impact of journal prestige was also evident: publications in high-impact factor (IF > 5) journals showed significantly better compliance in stakeholder involvement (Item 1: χ(2) = 8.856, P = 0.003) but comparable adherence to protocol registration (Item 23: ≤ 20.3%). CONCLUSIONS: While RR quality is improving post-2021, critical gaps persist in stakeholder engagement and protocol transparency. Mandatory adoption of Cochrane guidelines-particularly protocol registration (Item23) and dual data extraction (Item17)-should be prioritized in journal submission policies.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。